Expanding on a partnership established in 2023, and following the closure of Bespak’s OINDP development facilities in North Carolina, CDMO Bespak and CRO OzUK say that they will now offer continuity of low global warming potential (LGWP) propellant development projects between the two companies, with projects started at OzUK facilities then transfering to Bespak for manufacture of clinical supply.
Both companies have recently put new LGWP filling lines into service. OzUK recently opened a new pilot scale facility for pilot and feasibility studies of both solution and suspension MDIs filled with LGWP propellants, and Bespak opening a new GMP filling line for HFA-152a at its Holmes Chapel, UK site.
Bespak CEO Christ Hirst commented, “We’re thrilled to partner with such a trusted and well-respected team. By drawing on OzUK’s know-how and recently expanded capabilities, this partnership strengthens the development pathway for vital low GWP pMDIs. We’re also excited to bring our end-to-end pMDI services fully into the UK, reflecting the manufacturing excellence we have here, and bringing the entire low GWP pMDI value chain together.”
OzUK Chief Operating Officer Robert Johnson said, “By partnering with Bespak, we can help drive the low GWP pMDI transition with agility here in the UK. We’re excited by what’s possible as we continue to deliver our service as an independent research centre, and in parallel, work with the trusted Bespak team to offer the most extensive reformulation service to our customers. This seamless offering from early-stage development to clinical and ultimately commercial supply in partnership with Bespak is a winning formula to support the transition to climate-friendly inhalers.”
Read the Bespak and OzUK press release.
